Mid
T
TWSTAI Stock Diagnostic Report
Twist Bio, and Gingko rise after agreements with Lilly TuneLab
[OR] TWST signed a collaboration agreement with Lilly TuneLab, driving its stock price higher.
View Source Article ↗AI CATALYST SCORE72 / 100Score computed by Sentinel V12
REFERENCE PRICE$146.42Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
Eli Lilly’s signing of a collaboration agreement with TuneLab serves to externally validate the technological capabilities of its proprietary platform, opening the door to increased future orders related to milestones and commercialization.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Twist Bioscience (TWST) signed an agreement with Tune Labs, Eli Lilly’s collaboration platform, to discover novel antibody drugs, fueling expectations of expanding DNA demand in the AI and pharmaceutical sectors and driving the stock price higher.